Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota.
Department of Cardiovascular Surgery, Mayo Clinic, Rochester, Minnesota.
Ann Thorac Surg. 2022 Feb;113(2):519-526. doi: 10.1016/j.athoracsur.2021.03.038. Epub 2021 Mar 25.
Obesity is highly prevalent in patients with obstructive hypertrophic cardiomyopathy (HCM). In this study, we investigated the impact of body mass index (BMI) in patients undergoing septal myectomy (SM) for obstructive HCM.
We reviewed 2746 patients who underwent transaortic SM for obstructive HCM from February 1993 through September 2018. Patients were stratified into 3 groups based on BMI (normal weight, <25 kg/m; overweight, 25 to <30 kg/m; and obese, ≥30 kg/m).
Preoperatively, the median left ventricular outflow tract gradient was 58 mm Hg, and there was no difference in gradients across BMI strata (P = .35). The percentage of obese patients with moderate or greater mitral valve regurgitation was lower (45.8%) compared with normal weight (52.9%) and overweight (55.4%) patients (P < .001). However, patients with a higher BMI were more likely to have New York Heart Association Functional Classification III/IV limitation at presentation (P < .001). After myectomy, anteroseptal thickness (P = .115) and left ventricular outflow tract gradient (P = .210) did not differ between groups. There were 14 (0.5%) deaths within 30 days postoperatively, and the risk was similar across BMI strata (P = .448). Model-estimated changes in average BMI at 10 years postprocedure showed stratum-specific increases ranging from 0.60 to 1.56 kg/m. During a median follow-up of 7.2 years (interquartile range, 3.2-13.3 years), a higher BMI was associated with reduced survival after adjusting for baseline covariates (P = .001).
SM is safe and effective in HCM patients with obesity, but the risk of late death increased with increasing BMI. Attention to risk factor management through weight loss may improve late results after SM.
肥胖症在梗阻性肥厚型心肌病(HCM)患者中非常普遍。本研究旨在探讨体质量指数(BMI)对梗阻性 HCM 患者行室间隔心肌切除术(SM)的影响。
我们回顾了 1993 年 2 月至 2018 年 9 月期间 2746 例行经主动脉 SM 治疗的梗阻性 HCM 患者。根据 BMI(正常体重,<25kg/m;超重,25~<30kg/m;肥胖,≥30kg/m)将患者分为 3 组。
术前,左心室流出道梯度的中位数为 58mmHg,不同 BMI 组之间梯度无差异(P=0.35)。中度或重度二尖瓣反流的肥胖患者比例(45.8%)低于正常体重(52.9%)和超重(55.4%)患者(P<0.001)。然而,BMI 较高的患者在就诊时更可能出现纽约心脏协会功能分类 III/IV 级限制(P<0.001)。行 SM 后,室间隔厚度(P=0.115)和左心室流出道梯度(P=0.210)在各组之间无差异。术后 30 天内有 14 例(0.5%)死亡,不同 BMI 组之间的风险无差异(P=0.448)。术后 10 年平均 BMI 的模型估计变化显示,特定于各层的增加范围为 0.601.56kg/m。在中位数为 7.2 年(四分位间距为 3.213.3 年)的随访期间,校正基线协变量后,较高的 BMI 与生存率降低相关(P=0.001)。
SM 治疗肥胖的 HCM 患者是安全有效的,但随着 BMI 的增加,晚期死亡风险增加。通过减肥来关注危险因素的管理可能会改善 SM 后的晚期结果。